Market Size of Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 4.10 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market Analysis
The Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 4.1% during the forecast period. The major factors driving the growth of the market in the Asia region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.
According to GLOBOCAN 2018, the major countries contributing to kidney cancer cases in Asia are China and Japan. These countries were among the highest cases of kidney cancer worldwide. Furthermore, according to the International Agency for Research on Cancer, in 2018, there were about 148,947 new kidney cancer cases and the mortality was approximately 79,149 cases in Asia.
Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the Asia-Pacific kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period.
Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Industry Segmentation
As per the scope of the report, kidney cancer is a type of cancer that starts in kidney cells. The kidney cancer therapeutics and diagnostics involve therapy and diagnostics methods that are used for the treatment of renal cancer. The Asia-Pacific kidney cancer therapeutics & diagnostics market is segmented by cancer type, therapeutic class, pharmacologic class, diagnostics, and geography.
| By Cancer Type | |
| Renal Cancer Carcinoma | |
| Clear Cell Renal Cell Carcinoma | |
| Papillary Renal Cell Carcinoma | |
| Chromophobe Renal Cell Carcinoma | |
| Other Cancer Types |
| By Therapeutic Class | |
| Targeted Therapy | |
| Immunotherapy |
| By Pharmacologic Class | |
| Angiogenesis Inhibitors | |
| Monoclonal Antibodies | |
| mTOR Inhibitors | |
| Cytokine Immunotherapy (IL-2) |
| By Diagnostics | |
| Biopsy | |
| Intravenous Pyelogram | |
| CT Scan | |
| Nephro-Ureteroscopy | |
| Ultrasound | |
| Other Diagnostics |
| Geography | ||||||||
|
Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market Size Summary
The Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market is poised for significant expansion, driven by an increasing incidence of kidney cancer and heightened research and development investments by pharmaceutical companies. The region, particularly China and Japan, contributes substantially to the global kidney cancer cases, influenced by lifestyle changes such as smoking, alcohol consumption, and rising obesity rates. These factors have led to a higher prevalence of renal cell carcinoma, the most common type of kidney cancer, predominantly affecting older adults. The market's growth is further supported by growing public awareness of cancer, an aging population, and the rising incidence of renal cancer, which collectively underscore the demand for effective therapeutics and diagnostics.
The competitive landscape of the Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market is moderately consolidated, with key players like Bayer AG, F. Hoffmann-La Roche Ltd, Eisai Co. Ltd, Novartis AG, and Pfizer Inc. leading the charge. These companies are focusing on product innovation and advanced technology development to enhance their market position. The market's growth trajectory is bolstered by ongoing research and development activities, which are crucial for introducing novel solutions to combat kidney cancer. As the market evolves, these factors are expected to sustain its expansion over the forecast period, addressing the increasing healthcare needs of the region's population.
Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Number of Kidney Cancer Cases
-
1.2.2 Increased R&D Expenditure of Pharmaceutical Companies
-
-
1.3 Market Restraints
-
1.3.1 High Cost Associated with Treatment
-
1.3.2 Preference for Generic Drugs
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Cancer Type
-
2.1.1 Renal Cancer Carcinoma
-
2.1.2 Clear Cell Renal Cell Carcinoma
-
2.1.3 Papillary Renal Cell Carcinoma
-
2.1.4 Chromophobe Renal Cell Carcinoma
-
2.1.5 Other Cancer Types
-
-
2.2 By Therapeutic Class
-
2.2.1 Targeted Therapy
-
2.2.2 Immunotherapy
-
-
2.3 By Pharmacologic Class
-
2.3.1 Angiogenesis Inhibitors
-
2.3.2 Monoclonal Antibodies
-
2.3.3 mTOR Inhibitors
-
2.3.4 Cytokine Immunotherapy (IL-2)
-
-
2.4 By Diagnostics
-
2.4.1 Biopsy
-
2.4.2 Intravenous Pyelogram
-
2.4.3 CT Scan
-
2.4.4 Nephro-Ureteroscopy
-
2.4.5 Ultrasound
-
2.4.6 Other Diagnostics
-
-
2.5 Geography
-
2.5.1 Asia-Pacific
-
2.5.1.1 China
-
2.5.1.2 Japan
-
2.5.1.3 India
-
2.5.1.4 Australia
-
2.5.1.5 South Korea
-
2.5.1.6 Rest of Asia-Pacific
-
-
-
Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market Size FAQs
What is the current Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market size?
The Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)
Who are the key players in Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market?
Pfizer Inc, F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG and Eisai.Co.Ltd are the major companies operating in the Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market.
